# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Adaptimmune Therapeutics shares are trading higher by 15.8% during Friday's session. The company and Galapagos entered a cl...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next gener...
Scotiabank analyst George Farmer initiates coverage on Adaptimmune Therapeutics (NASDAQ:ADAP) with a Sector Outperform ratin...
Mizuho analyst Graig Suvannavejh maintains Adaptimmune Therapeutics (NASDAQ:ADAP) with a Buy and lowers the price target fro...
Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate...